CLINICAL RESPONSE TO INTRAVENOUS
IMMUNOGLOBULIN IN ACUTE INFLAMMATORY
DEMYELINATING POLYRADICULONEUROPATHY
IOAN BURAGA 1, ROXANA-ELENA MARTIN 1*, ADRIAN
DOBRESCU 1, IOANA BURAGA 2
1Department of Neurology, Colentina Clinical Hospital, No.19-21 Stefan
cel Mare Str., RO-020125, Bucharest
2Department of ATI, Colentina Clinical Hospital, No.19-21 Stefan cel
Mare Str., RO-020125, Bucharest
*corresponding author: doctor_roxi@yahoo.co.uk
Download Full Article

Abstract:

IImmunoglobulin pharmaceutical preparations are sterile concentrated antibodies. Intravenous immunoglobulin (IV Ig) exerts its effect through modulation of expression and function of Fc receptors, interference with complement activation and the cytokine network, provision of
antiidiotypic antibodies, modulation of T and B cell activation. The efficacy of IV Ig has been proved to be grade A recommendation for the Guillain-Barré Syndrome (GBS) and chronic inflammatory demyelinating polyneuropathies. GBS is an acute inflammatory disorder of the peripheral nervous system thought to be due to autoimmunity. This etiology led to our study where we investigated the timing, course and clinical characteristics of the response to intravenous immunoglobulin. We examined retrospectively the records of 69 patients with GBS. Every patient received 0.4g/kg body weight immunoglobulin, for 5 days, every 4 weeks for up to 20 weeks. The data revealed that more participants responded after the second courses of IV Ig treatment. Treatment with intravenous
immunoglobulin in the first two weeks from symptoms onset has proved efficient in shortening recovery time in patients with GBS.

Top